The CLIP1- LTK fusion: a new oncogenic driver in non-small-cell lung cancer?

Future Oncol. 2023 Feb;19(4):273-275. doi: 10.2217/fon-2022-1232. Epub 2023 Mar 21.

Authors

Rebecca Ibrahim¹, Claude Chahine¹, Tony Felefly², Nadine Khalife³, Khalil Saleh¹

Affiliations

¹ International Department, Gustave Roussy Cancer Campus, Villejuif, 94800, France.
² Radiation Oncology Department, Saint-Joseph University, Beyrouth, 1100, Lebanon.
³ Department of Head & Neck Oncology, Gustave Roussy Cancer Campus, Villejuif, 94800, France.

PMID: 36942735
DOI: 10.2217/fon-2022-1232

No abstract available

Keywords: ALK fusion; CLIP1-LTK fusion; lorlatinib; non-small-cell lung cancer; tyrosine kinase inhibitors.

Publication types

Editorial
Comment

MeSH terms

Aminopyridines / therapeutic use
Anaplastic Lymphoma Kinase
Antineoplastic Agents* / therapeutic use
Carcinoma, Non-Small-Cell Lung* / drug therapy
Carcinoma, Non-Small-Cell Lung* / genetics
Carcinoma, Non-Small-Cell Lung* / surgery
Humans
Lactams, Macrocyclic / therapeutic use
Lung Neoplasms* / drug therapy
Lung Neoplasms* / genetics
Lung Neoplasms* / surgery
Protein Kinase Inhibitors / therapeutic use
Receptor Protein-Tyrosine Kinases

Substances

Antineoplastic Agents
Anaplastic Lymphoma Kinase
Protein Kinase Inhibitors
Aminopyridines
Lactams, Macrocyclic
LTK protein, human
Receptor Protein-Tyrosine Kinases